AC Immune (ACIU) Cash from Discontinued Operations (2015 - 2025)
AC Immune (ACIU) posted quarterly Cash from Discontinued Operations of 140839838.12 for Q3 2025, down 217.19% year-over-year from 120181829.23 in Q3 2024, and down 538.24% quarter-over-quarter from 22067050.63 in Q1 2025.
Powered by 
Analysis
AC Immune (ACIU) Cash from Discontinued Operations (2015 - 2025) Analysis & Trends
AC Immune (ACIU) has reported Cash from Discontinued Operations for 11 consecutive years, with 140839838.12 the latest figure, recorded in Q3 2025.
- In Q3 2025, Cash from Discontinued Operations fell 217.19% year-over-year to 140839838.12; the TTM figure through Sep 2025 stood at 41551880.84 (down 146.6% YoY), while the FY2016 annual figure was 62665810.51, up 36.72% from the prior year.
- Cash from Discontinued Operations slipped to 140839838.12 in Q3 2025 per ACIU's latest filing, from 22067050.63 in the prior quarter.
- Across five years, Cash from Discontinued Operations topped out at 120181829.23 in Q3 2024 and bottomed at 140839838.12 in Q3 2025.
- Historically, Cash from Discontinued Operations has averaged 15596427.99 across 5 years, with a median of 18164612.47 in 2023.
- Annual changes were most pronounced in 2024 — Cash from Discontinued Operations surged 106.46% — and 2025, when it sank 1980.96%.
- AC Immune's Cash from Discontinued Operations stood at 15791282.96 in 2021, then increased by 11.24% to 14016976.47 in 2022, then dropped by 29.59% to 18164612.47 in 2023, then soared by 761.63% to 120181829.23 in 2024, then plunged by 217.19% to 140839838.12 in 2025.
- Business Quant data shows ACIU's Cash from Discontinued Operations at 140839838.12 in Q3 2025, 22067050.63 in Q1 2025, and 120181829.23 in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | AC Immune | 285.13 Mn | 285.13 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -140.84 Mn |
| Mar 31, 2025 | -22.07 Mn |
| Sep 30, 2024 | 120.18 Mn |
| Mar 31, 2024 | 1.17 Mn |
| Mar 31, 2023 | -18.16 Mn |
| Sep 30, 2022 | -14.02 Mn |
| Jun 30, 2022 | -20.23 Mn |
| Mar 31, 2022 | -25.06 Mn |
| Sep 30, 2021 | -15.79 Mn |
| Jun 30, 2021 | -17.57 Mn |
| Mar 31, 2021 | -19.18 Mn |
| Sep 30, 2020 | -16.94 Mn |
| Jun 30, 2020 | -15.43 Mn |
| Mar 31, 2020 | -10.01 Mn |
| Sep 30, 2019 | 17.27 Mn |
| Jun 30, 2019 | -14.99 Mn |
| Mar 31, 2019 | 66.25 Mn |
| Sep 30, 2018 | -12.04 Mn |
| Jun 30, 2018 | -7.25 Mn |
| Mar 31, 2018 | -14.07 Mn |